Insiders Trades
AN
Alzamend Neuro, Inc. Stock: price and insider trades · United States
1 insider bought €188k of shares over the last 90 days, the latest filed 31 Aug 2026.
Alzamend Neuro, Inc.: what insiders have been doing
Alzamend Neuro, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 3 insiders have disclosed 6 filings since 18 October 2025.
Open-market activity splits into 2 purchases totalling €94k and 4 sales totalling €12k; 1 insider sit on the buying side and 3 insiders on the selling side. Netting one side against the other leaves €82k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a purchase of €92k by Ault Milton C III, published on 16 April 2026, equal to 1.5% of the market capitalisation. Among those who bought: 1 senior executive.
The most recent open-market purchase was published on 31 August 2026, 47 days ago. The median gap between a trade and its publication by SEC (Form 4) is 5 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 6 filings here. Looking back to 2021, when coverage begins, insiders filed 90 purchases and 15 sales. For the fiscal year to 30 April 2026, the annual 10-K puts net income at -8.8 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
137
Thresholds
n/a
Buy Volume
€6M
90 ops. · all time
Sell Volume
€624,582
15 ops. · all time
Who traded when
BuySaleMilton C. Ault III8 buys10 sales
William B. Horne2 buys1 sale
David J. Katzoff1 buy
Lynne Fahey McGrath1 sale
Since the insiders bought
- -18.1%Entry US$1.64 · Close 16 Oct 2026 US$1.34
- -88.9%Entry US$9.54 · Close at T+365 US$1.06
- -78.8%Entry US$9.09 · Close at T+365 US$1.93
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended April 2026 · cache
US$1.28
Analyst consensus
1 analysts1.00/5
US$26.00Target US$26.00(+1931%)US$26.00
Income statement
EBITDA-US$8.7M
Net income-US$8.8M0.0% margin
Valuation
PER (forward)-1.5x
P/Book1.1x
Beta0.27
Balance sheet & cash
Market capUS$6.2M
Total debtUS$300.7k
Free Cash Flow-US$8.1M
Profitability & ownership
ROE-163.2%
ROA-76.4%
% insiders2.7%
% institutions56.4%
Last declaration on 31 August 2026
Declarations137 total
2,000 shares@ US$1.55810.034% mcap0.0% of flowCommon StockSEC:0001214659-26-011121:0
2,000 shares@ US$1.03380.0% of flowCommon StockSEC:0001214659-26-011110:1
Canonical exit: 13 Jul 2026 (T+90)
108,388 shares@ US$1.00471.54% mcap1.0% of flowCommon StockSEC:0001214659-26-004742:0
Canonical exit: 13 Jul 2026 (T+90)
1,851 shares@ US$2.06650.0% of flowCommon StockSEC:0001214659-25-018631:0
3,333 shares@ US$2.117836.2% of flowCommon StockSEC:0001214659-25-018437:0
30 shares@ US$2.290.2% of flowCommon StockSEC:0001214659-25-015288:0
61,743 shares@ US$2.321.4% of flowCommon StockSEC:0001214659-25-014861:0
100,000 shares@ US$2.322.2% of flowCommon StockSEC:0001214659-25-014752:0
100,000 shares@ US$2.322.2% of flowCommon StockSEC:0001214659-25-014629:0
37,738 shares@ US$2.31450.8% of flowCommon StockSEC:0001214659-25-014420:0
38,324 shares@ US$2.3090.8% of flowCommon StockSEC:0001214659-25-014420:1
3,566 shares@ US$2.33340.1% of flowCommon StockSEC:0001214659-25-014420:2
43,238 shares@ US$2.37571.0% of flowCommon StockSEC:0001214659-25-014210:0
77,009 shares@ US$2.34851.7% of flowCommon StockSEC:0001214659-25-014056:0
100,000 shares@ US$2.322.2% of flowCommon StockSEC:0001214659-25-014056:1
100,000 shares@ US$2.322.2% of flowCommon StockSEC:0001214659-25-013976:0
100,000 shares@ US$2.322.3% of flowCommon StockSEC:0001214659-25-011356:0
36,532 shares@ US$2.89761.0% of flowCommon StockSEC:0001214659-25-011043:0
8,311 shares@ US$2.68490.2% of flowCommon StockSEC:0001214659-25-011043:1
143,429 shares@ US$2.323.2% of flowCommon StockSEC:0001214659-25-010933:0
1,213 shares@ US$5.06040.1% of flowCommon StockSEC:0001214659-25-007625:0
3,334 shares@ US$0.985418.3% of flowCommon StockSEC:0001214659-25-004857:0
Canonical exit: 24 Jun 2025 (T+90)
2,905 shares@ US$1.0220.0% of flowCommon StockSEC:0001214659-25-004752:0
Canonical exit: 19 Jun 2025 (T+90)
5,000 shares@ US$1.009618.3% of flowCommon StockSEC:0001214659-25-004643:0
Canonical exit: 19 Jun 2025 (T+90)
5,000 shares@ US$0.978327.0% of flowCommon StockSEC:0001214659-25-004592:0
Canonical exit: 18 Jun 2025 (T+90)
25 of 137 declarations
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc. (ticker: ALZN) is a U.S.-based clinical-stage biopharmaceutical company listed on Nasdaq in the United States. For French-speaking investors, it is a very small-cap healthcare name whose investment case is driven primarily by clinical execution, regulatory progress, and financing capacity rather than commercial sales. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia, with historical ties to Florida and ongoing collaboration with major U.S. research institutions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1677077/000121465925010763/u7925110k.htm?utm_source=openai))
Alzamend’s strategy is narrowly focused on neurodegenerative and psychiatric disorders, especially Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its current pipeline is centered on two main programs. AL001 is a patented ionic cocrystal lithium formulation combining lithium, salicylate, and L-proline, designed to improve delivery of lithium to the brain while reducing systemic exposure compared with conventional lithium carbonate. ALZN002 is a cell-based therapeutic vaccine approach using a mutant-peptide-sensitized cell intended to help restore the patient’s immune response and remove beta-amyloid from the brain. Both candidates are licensed from the University of South Florida Research Foundation under royalty-bearing exclusive worldwide licenses. ([ir.alzamend.com](https://ir.alzamend.com/news-events/press-releases/detail/97/alzamend-neuro-announces-completion-of-clinical-portion-of?utm_source=openai))
Read moreShow less
From a competitive standpoint, Alzamend occupies a highly specialized and speculative niche in CNS drug development: next-generation lithium delivery and an Alzheimer’s immunotherapy concept. The company does not yet have a marketed product, so the investment thesis depends on clinical readouts, regulatory milestones, and its ability to fund development over time. That makes the story high-risk/high-reward, with material dilution and execution risk typical of early-stage biotech issuers. ([ir.alzamend.com](https://ir.alzamend.com/company-information?utm_source=openai))
Recent developments have been important for the stock narrative. In 2025 and 2026, Alzamend reported multiple Phase II updates for AL001, including initiation and completion of clinical work and, most notably, preliminary positive data showing bioequivalence and numerically superior brain delivery versus standard lithium carbonate across the measured brain regions. The company also announced that it had regained compliance with Nasdaq listing standards in October 2024. These milestones improve the clinical profile, but they do not remove the inherent binary risk associated with a development-stage biotech company. ([ir.alzamend.com](https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
